英夫利昔单抗治疗瘘管型克罗恩病后出现的巨噬细胞活化综合征
[Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease].
作者信息
Chauveau Eric, Terrier François, Casassus-Buihle Didier, Moncoucy Xavier, Oddes Bernard
机构信息
Service des maladies digestives et tropicales, Hôpital d'Instruction des Armées Robert Picqué 33998 Bordeaux Armées.
出版信息
Presse Med. 2005 Apr 23;34(8):583-4. doi: 10.1016/s0755-4982(05)83984-3.
INTRODUCTION
Macrophage activation syndrome has never been reported as an adverse effect of infliximab.
CASE
Treatment with infliximab was prescribed for a 37-year-old man with fistulated Crohn's disease unresponsive to azathioprine. Three months after the last injection, he developed macrophagic activation syndrome, with febrile pancytopenia, hyperferritinemia, hypertriglyceridemia and an activated cephalin time twice the control level.
DISCUSSION
Elimination of the known causes of macrophage activation syndrome suggests it is related to the infliximab treatment, but its pathogenesis remains a mystery.
引言
巨噬细胞活化综合征从未被报道为英夫利昔单抗的不良反应。
病例
一名37岁患有瘘管性克罗恩病且对硫唑嘌呤无反应的男性患者接受了英夫利昔单抗治疗。最后一次注射三个月后，他出现了巨噬细胞活化综合征，伴有发热性全血细胞减少、高铁蛋白血症、高甘油三酯血症以及活化部分凝血活酶时间为对照水平的两倍。
讨论
排除巨噬细胞活化综合征的已知病因后提示其与英夫利昔单抗治疗有关，但其发病机制仍是个谜。
Zotero 插件